Nearly 15% of invasive breast cancers are devoid of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor type 2 (HER2) expression and, thus, defined as triple-negative breast cancer (TNBC) [1]. Here, ESR1 is linked to triple-negative breast carcinoma.